Consistent with this, the level of nuclear Nrf2 is reduced in the hippocampus of Alzheimer’s disease (AD) brain [12], and attenuation of the Nrf2-ARE pathway coincides with disease progression in transgenic AD mice [13, 14], while genetic ablation of Nrf2 increases AD-associated pathology in AD mice [15]. This evidence concerns the gene NFE2L2 and early-onset autosomal dominant Alzheimer disease.